Get the Stockscreener App
32.90
6.33%
1.96
After Hours:
32.89
-0.010
-0.03%
Tango Therapeutics Inc stock is traded at $32.90, with a volume of 3.22M.
It is up +6.33% in the last 24 hours and up +60.02% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$30.94
Open:
$31.33
24h Volume:
3.22M
Relative Volume:
0.89
Market Cap:
$5.36B
Revenue:
$56.99M
Net Income/Loss:
$-107.23M
P/E Ratio:
-40.13
EPS:
-0.8199
Net Cash Flow:
$-142.55M
1W Performance:
+6.37%
1M Performance:
+60.02%
6M Performance:
+260.75%
1Y Performance:
+601.49%
1-Day Range:
$30.75
$33.00
1-Week Range:
$28.07
$33.00
52-Week Range:
$4.40
$33.00
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
32.90 | 5.04B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-26 | Initiated | Canaccord Genuity | Buy |
| Feb-23-26 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66 - Moomoo
Tango Therapeutics prices upsized $600M public offering at $30/share - MSN
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
[144] Tango Therapeutics, Inc. SEC Filing - Stock Titan
Tango Therapeutics Announces Major Underwritten Equity Offering - TipRanks
Tango Therapeutics Prices $600 Million Stock Offering - Moomoo
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66 - Moomoo
Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted - TradingView
Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering - Stock Titan
Tango Therapeutics (TNGX) raises ~$566.5M via 18.17M shares and pre-funded warrants - Stock Titan
Insider sale notice — TNGX (NASDAQ:TNGX) reports planned share sales - Stock Titan
Tango Therapeutics stock price target raised to $66 by H.C. Wainwright on trial data - Investing.com
Tango Therapeutics stock hits all-time high at 32.69 USD By Investing.com - Investing.com India
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year - Yahoo Finance
Tango Therapeutics prices $600M upsized public offering - scanx.trade
Tango Therapeutics prices $600 million stock offering - Investing.com India
Tango Therapeutics prices $600 million stock offering By Investing.com - Investing.com India
Tango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering - The Manila Times
Tango Therapeutics Expects Gross Proceeds of About $600M From Offering >TNGX - Moomoo
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering - GlobeNewswire Inc.
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates - Stocktwits
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Tango Therapeutics launches $500 million stock offering By Investing.com - Investing.com Australia
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite (TNGX) - Seeking Alpha
Tango Therapeutics stock rockets 53% on pancreatic cancer data - grafa.com
TNGX Maintained by HC Wainwright & Co. -- Price Target Raised to $66 - GuruFocus
Tango Therapeutics stock hits all-time high at 32.69 USD - Investing.com
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results - Yahoo Finance
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $42 - GuruFocus
Tango Therapeutics stock surges on pancreatic cancer trial data - qz.com
Tango Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results - Barchart.com
Canaccord raises Tango Therapeutics stock price target on drug combo By Investing.com - Investing.com Nigeria
Canaccord raises Tango Therapeutics stock price target on drug combo - Investing.com
B. Riley Raises Price Target on Tango Therapeutics to $35 From $21, Keeps Buy Rating - marketscreener.com
Tango Therapeutics Stock Soars 53% After Pancreatic Cancer Trial Stuns Wall Street - TIKR.com
Tango Therapeutics Shares Surge 53% on Promising Pancreatic Cancer Trial Data - International Business Times Australia
Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data Prospects - simplywall.st
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are - Benzinga
Tango Therapeutics stock soars on promising pancreatic cancer data - CryptoRank
TNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’ - MSN
Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer - BioCentury
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36.91, Implies 83% Upside - TradingView
Tango Therapeutics (TNGX) director receives 4,000 RSUs and 25,000-share option grant - Stock Titan
Tango Therapeutics (TNGX) director awarded RSUs and 25,000 stock options - Stock Titan
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):